JOP20240057A1 - مشتقات الأمين الحلقية كمُعدِلات لمُستقبِل GABAA α5 - Google Patents

مشتقات الأمين الحلقية كمُعدِلات لمُستقبِل GABAA α5

Info

Publication number
JOP20240057A1
JOP20240057A1 JOJO/P/2024/0057A JOP20240057A JOP20240057A1 JO P20240057 A1 JOP20240057 A1 JO P20240057A1 JO P20240057 A JOP20240057 A JO P20240057A JO P20240057 A1 JOP20240057 A1 JO P20240057A1
Authority
JO
Jordan
Prior art keywords
gabaa
receptor modulators
stereoisomers
preparation
receptor
Prior art date
Application number
JOJO/P/2024/0057A
Other languages
Arabic (ar)
English (en)
Inventor
Péter Erdélyi
Olivér Éliás
Imre Bata
Attila Potor
György István Túrós
György Szabó
Gábor László Kapus
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of JOP20240057A1 publication Critical patent/JOP20240057A1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JOJO/P/2024/0057A 2021-09-29 2024-03-20 مشتقات الأمين الحلقية كمُعدِلات لمُستقبِل GABAA α5 JOP20240057A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP2100338A HU231691B1 (hu) 2021-09-29 2021-09-29 GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
PCT/IB2022/059214 WO2023053015A1 (en) 2021-09-29 2022-09-28 BICYCLIC AMINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS

Publications (1)

Publication Number Publication Date
JOP20240057A1 true JOP20240057A1 (ar) 2024-03-20

Family

ID=89993434

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2024/0057A JOP20240057A1 (ar) 2021-09-29 2024-03-20 مشتقات الأمين الحلقية كمُعدِلات لمُستقبِل GABAA α5

Country Status (21)

Country Link
US (1) US20250051323A1 (https=)
EP (1) EP4408842A1 (https=)
JP (1) JP2024536039A (https=)
KR (1) KR20240089056A (https=)
CN (1) CN118284606A (https=)
AR (1) AR127182A1 (https=)
AU (1) AU2022357572A1 (https=)
CA (1) CA3231776A1 (https=)
CL (1) CL2024000893A1 (https=)
CO (1) CO2024005424A2 (https=)
CU (1) CU20240013A7 (https=)
EC (1) ECSP24032316A (https=)
GE (2) GEP20257812B (https=)
HU (1) HU231691B1 (https=)
IL (1) IL311640A (https=)
JO (1) JOP20240057A1 (https=)
MX (1) MX2024003812A (https=)
PE (1) PE20240816A1 (https=)
TW (1) TW202330518A (https=)
WO (1) WO2023053015A1 (https=)
ZA (1) ZA202403230B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119080754A (zh) * 2023-06-05 2024-12-06 武汉人福创新药物研发中心有限公司 作为α5-GABAA受体调节剂的杂环化合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230518B1 (hu) 2005-12-20 2016-10-28 Richter Gedeon Nyrt. Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények
HUP0600809A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600808A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
US8742097B2 (en) 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
US9475797B2 (en) 2012-06-26 2016-10-25 Saniona A/S Phenyl triazole derivative and its use for modulating the GABAA receptor complex
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
HUP1300139A2 (en) 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
NZ760341A (en) 2013-12-20 2021-12-24 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HRP20221098T1 (hr) 2016-03-18 2022-11-25 Uwm Research Foundation, Inc. Tretman kognitivnih i simptoma poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5
ES2910110T3 (es) 2016-12-08 2022-05-11 Hoffmann La Roche Nuevos derivados de isoxazolil-éter como PAM de alfa 5 GABA A
HU231058B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt. Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素V1a受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
IL279266B2 (en) 2018-06-13 2024-03-01 Hoffmann La Roche New isoxazolyl ether derivatives as gaba a alpha5 pam
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) * 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
TWI901650B (zh) * 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物

Also Published As

Publication number Publication date
MX2024003812A (es) 2024-04-25
GEAP202416510A (en) 2024-08-12
CU20240013A7 (es) 2024-11-15
WO2023053015A1 (en) 2023-04-06
HU231691B1 (hu) 2025-10-28
CL2024000893A1 (es) 2024-09-06
US20250051323A1 (en) 2025-02-13
KR20240089056A (ko) 2024-06-20
TW202330518A (zh) 2023-08-01
CN118284606A (zh) 2024-07-02
AU2022357572A1 (en) 2024-05-02
PE20240816A1 (es) 2024-04-18
JP2024536039A (ja) 2024-10-04
EP4408842A1 (en) 2024-08-07
ZA202403230B (en) 2024-12-18
HUP2100338A1 (hu) 2023-04-28
GEP20257812B (en) 2025-10-27
ECSP24032316A (es) 2024-05-31
IL311640A (en) 2024-05-01
CO2024005424A2 (es) 2024-05-10
CA3231776A1 (en) 2023-04-06
AR127182A1 (es) 2023-12-27

Similar Documents

Publication Publication Date Title
MX2022012306A (es) Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades.
EA202092169A1 (ru) ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ АМИНОПРОПИОНАТНЫХ СОЕДИНЕНИЙ В ЛЕЧЕНИИ ИНФЕКЦИИ SARS-CoV-2
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
BR112014025564A8 (pt) composto heterocíclico contendo nitrogênio ou sal do mesmo
EA202191188A1 (ru) Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения
JOP20220281A1 (ar) مركبات وتركيبات لتثبيط نشاط hif2 ألفا وطرق لاستخدامها
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
MA49127B1 (fr) Dérivés d'indole n-substitués
JOP20240217A1 (ar) مشتقات الكوينولين كمُعدِّلات للعضو x2 لمستقبل بروتين g مرتبط بـ mas ومنتجات ذات صلة
SA521431279B1 (ar) D1 مشتق تتراهيدرو إيزوكينولين بديل كمعدِّل تفارغي إيجابي
DOP2019000076A (es) DERIVADOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANOS COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE mGluR2, COMPOSICIONES Y SU USO
EP4635494A3 (en) AMIDO HETERO-ROMATIC COMPOUNDS
JOP20240057A1 (ar) مشتقات الأمين الحلقية كمُعدِلات لمُستقبِل GABAA α5
MX2022004878A (es) Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos.
SA522432749B1 (ar) I/alk5 مشتقات بنزيلاميد كمستقبل لمثبطات عامل النمو المتحول-بيتا
CO2025003090A2 (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
MX2025011458A (es) Inhibidor de cyp11a1 y uso del mismo
EA202190857A1 (ru) Бициклические производные как модуляторы 5 рецепторов gabaa
EA202190064A1 (ru) Цианотриазоловые соединения и варианты их применения
MX2025011499A (es) Forma de cristal de sal de compuesto de anillo fusionado cuaternario, y método de preparación y uso del mismo
MX2023005071A (es) Amidas de isoquinolina enlazadas a n como inhibidores de lrrk2, composiciones farmaceuticas y usos de las mismas.
EA202090925A1 (ru) Гетероарильные соединения в качестве позитивных аллостерических модуляторов мускаринового рецептора m1
PH12022552340A1 (en) APHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA a5 RECEPTOR MODULATORS
MX2023015246A (es) Compuestos pirimidinicos para usar como inhibidores de map4k1.
MX2024009077A (es) Compuestos de benzotiazol y benzoisoxazola para el tratamiento de trastornos mentales.